Concepts (60)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 2 | 2009 | 196 | 0.470 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2015 | 51 | 0.410 |
Why?
|
| Adenine Nucleotides | 1 | 2009 | 3 | 0.310 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 33 | 0.310 |
Why?
|
| Arabinonucleosides | 1 | 2009 | 7 | 0.310 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2005 | 3 | 0.230 |
Why?
|
| Thalidomide | 1 | 2005 | 7 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 240 | 0.160 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 55 | 0.110 |
Why?
|
| Adult | 6 | 2015 | 6826 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 14 | 0.100 |
Why?
|
| Transcriptome | 1 | 2012 | 53 | 0.090 |
Why?
|
| Cytokines | 1 | 2012 | 200 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 3 | 0.090 |
Why?
|
| Vincristine | 2 | 2011 | 23 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2011 | 26 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2011 | 44 | 0.080 |
Why?
|
| Rituximab | 2 | 2011 | 38 | 0.080 |
Why?
|
| Prednisone | 2 | 2011 | 64 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2011 | 57 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 9 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 15 | 0.060 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2006 | 32 | 0.060 |
Why?
|
| Lymphatic Irradiation | 1 | 2005 | 1 | 0.060 |
Why?
|
| Axilla | 1 | 2005 | 12 | 0.060 |
Why?
|
| Etoposide | 1 | 2005 | 27 | 0.060 |
Why?
|
| Carboplatin | 1 | 2005 | 24 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2005 | 13 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 104 | 0.060 |
Why?
|
| Humans | 6 | 2015 | 22592 | 0.060 |
Why?
|
| Remission Induction | 1 | 2005 | 89 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 58 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2005 | 50 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 292 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 163 | 0.050 |
Why?
|
| Male | 5 | 2015 | 12260 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 242 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 165 | 0.050 |
Why?
|
| Prognosis | 2 | 2015 | 719 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2006 | 804 | 0.040 |
Why?
|
| Middle Aged | 4 | 2015 | 7800 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2015 | 2915 | 0.040 |
Why?
|
| Aged | 3 | 2015 | 7300 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2012 | 6 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 455 | 0.020 |
Why?
|
| Female | 3 | 2015 | 12734 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 2011 | 4 | 0.020 |
Why?
|
| Leukopenia | 1 | 2011 | 7 | 0.020 |
Why?
|
| Neutropenia | 1 | 2011 | 16 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 19 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 151 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 517 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 208 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 369 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1403 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2006 | 10 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 50 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 431 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 3657 | 0.010 |
Why?
|